GenSight Biologics to Present GS010 at the 4th Annual Retinal Cell & Gene Therapy Innovation Summit

Paris, France, April 27, 2017, 7.30 CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, today announced that an abstract was accepted for an oral presentation at the 4th Annual Retinal Cell & Gene Therapy  Innovation Summit in Baltimore, MD, May 4-5, 2017. Please find the full PDF press release attached. Contacts GenSight Biologics Thomas Gidoin Chief Financial Officer ir@gensight-biologics.com +33 (0)1 76 21 72 20 NewCap Investor Relations Florent Alba gensight@newcap.eu +33 (0)1 44 71 98 55 Rooney Partners Media Relations Marion Janic mjanic@rooneyco.com +1-212-223-4017

---

Source: Gensight